- $445.91m
- $387.58m
- $180.46m
Brief: Kamada Sees FY 2020 Revenue $132 Million To $137 Million
Plasma therapy developers jump as U.S. authorizes plasma treatment for COVID-19
Brief: Kamada, Kedrion Biopharma Announce Results Of U.S. Post-Marketing Pediatric Trial Of A Human Rabies Immune Globulin
Brief: Kamada Announces Changes To Its Board Of Directors
Brief: Kamada Announces Enrollment Of First Patient In Phase 1/2 Clinical Trial For Covid-19
Brief: Kamada Announces Availability Of Its Plasma-Derived Hyperimmune IgG Therapy For COVID-19 For Compassionate Use Treatment In Israel
Brief: Kamada Reports Q1 EPS Of $0.12
Brief: Kamada And Kedrion Biopharma Announce Global Collaboration For The Development, Manufacturing And Distribution Of A Plasma-Derived Anti-Sars-Cov-2 (Covid-19) Polyclonal Immunoglobulin Product
Brief: Kamada Q4 Revenue Fell 33% To $32.1 Mln
Brief: Kamada Sees FY 2020 Revenue Between $132 Million To $137 Million
Brief: Kamada Announces Enrollment Of First Patient Into Its Pivotal Phase 3 Clinical Trial Of Inhaled Aat For The Treatment Of Alpha-1 Antitrypsin Deficiency
Brief: Kamada Enters Into A Binding Term Sheet For Contract Manufacturing Of Commercialized Hyper-Immune Globulin Product
Brief: Ishay Davidi Reports A 12.9% Stake In Kamada As Of Nov. 21
Brief: Kamada Reports Q3 EPS Of $0.14
Brief: Kamada Says Will Now Continue To Produce Glassia For Takeda Through 2021
Brief: Kamada Reports Discussions With Takeda Regarding A Potential Extension Of The Period For The Transition Of Glassia Manufacturing To Takeda
Brief: Kamada Reports Financial Results For Second Quarter And First Six Months Of 2019
Brief: Kamada Q1 Earnings Per Share $0.12
U.S. STOCKS ON THE MOVE-Netflix, Johnson & Johnson, UnitedHealth, Bristow